Published in Mol Immunol on July 01, 2004
Cytokine signaling modules in inflammatory responses. Immunity (2008) 4.09
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood (2011) 1.86
Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity. J Exp Med (2008) 1.83
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood (2005) 1.73
A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Blood (2014) 1.58
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood (2009) 1.16
Interlinking interleukin-7. Cytokine (2007) 1.14
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res (2014) 0.99
The use of structural biology in Janus kinase targeted drug discovery. Curr Drug Targets (2011) 0.99
The molecular regulation of Janus kinase (JAK) activation. Biochem J (2014) 0.95
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia (2010) 0.93
The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells. J Immunol (2013) 0.91
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91
A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation. J Biol Chem (2011) 0.87
In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection. PLoS Pathog (2014) 0.85
Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients. Am J Kidney Dis (2009) 0.83
Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol (2012) 0.83
Human lymphoid development in the absence of common γ-chain receptor signaling. J Immunol (2014) 0.80
Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.77
Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells. Cell Mol Immunol (2012) 0.75
Pharmacophore and Virtual Screening of JAK3 inhibitors. Bioinformation (2014) 0.75
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol (2009) 3.91
Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A (2006) 3.66
Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science (2002) 3.05
Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med (2014) 2.71
Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood (2009) 2.26
Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation (2004) 2.18
Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood (2002) 2.11
Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med (2014) 1.81
How I treat ADA deficiency. Blood (2009) 1.70
Gene therapy: X-SCID transgene leukaemogenicity. Nature (2006) 1.57
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Pain management principles in the critically ill. Chest (2009) 1.51
Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol (2007) 1.40
Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol (2002) 1.40
The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol (2013) 1.40
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency. J Clin Invest (2017) 1.39
Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol (2004) 1.39
T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation. J Immunol (2003) 1.39
Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest (2007) 1.39
Evaluation of pain in ICU patients. Chest (2009) 1.36
The altered landscape of the human skin microbiome in patients with primary immunodeficiencies. Genome Res (2013) 1.35
B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol (2013) 1.33
Sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 are vital to recovery from anaphylactic shock in mice. J Clin Invest (2010) 1.31
Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet (2008) 1.31
Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol (2010) 1.30
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther (2003) 1.29
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev (2005) 1.28
Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther (2002) 1.27
Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol (2003) 1.27
B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood (2012) 1.27
Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood (2003) 1.26
Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol (2008) 1.25
Nuclear role of WASp in the pathogenesis of dysregulated TH1 immunity in human Wiskott-Aldrich syndrome. Sci Transl Med (2010) 1.24
Gene therapy fulfilling its promise. N Engl J Med (2009) 1.24
Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol (2009) 1.23
Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol (2003) 1.20
Efficient methods for targeted mutagenesis in zebrafish using zinc-finger nucleases: data from targeting of nine genes using CompoZr or CoDA ZFNs. PLoS One (2013) 1.19
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol (2007) 1.18
Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO). Pediatr Rheumatol Online J (2013) 1.17
Shifting HIFs in osteoarthritis. Nat Med (2010) 1.17
The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol (2004) 1.16
T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. Blood (2006) 1.15
New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol (2005) 1.15
The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant (2004) 1.14
Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-Aldrich syndrome protein. Blood (2010) 1.14
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol (2012) 1.12
A novel form of complete IL-12/IL-23 receptor beta1 deficiency with cell surface-expressed nonfunctional receptors. Blood (2004) 1.12
A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol (2004) 1.11
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther (2008) 1.10
Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol (2011) 1.08
Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. J Clin Invest (2003) 1.08
Revertant somatic mosaicism in the Wiskott-Aldrich syndrome. Immunol Res (2009) 1.05
Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome. Blood (2005) 1.04
Somatic mosaicism in primary immune deficiencies. Curr Opin Allergy Clin Immunol (2008) 1.03
Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections. N Engl J Med (2015) 1.02
CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proc Natl Acad Sci U S A (2012) 0.99
Structured approaches to pain management in the ICU. Chest (2009) 0.96
Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. J Allergy Clin Immunol (2007) 0.96
The expression of Wiskott-Aldrich syndrome protein (WASP) is dependent on WASP-interacting protein (WIP). Int Immunol (2007) 0.96
Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood (2006) 0.95
CXCL12 signaling is independent of Jak2 and Jak3. J Biol Chem (2004) 0.95
Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family. Blood (2004) 0.94
Cartilage hair hypoplasia mutations that lead to RMRP promoter inefficiency or RNA transcript instability. Am J Med Genet A (2007) 0.94
Abnormal development of thymic dendritic and epithelial cells in human X-linked severe combined immunodeficiency. Clin Immunol (2004) 0.93
Lessons from the Wiskott-Aldrich syndrome. N Engl J Med (2006) 0.92
Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome. Mol Ther (2012) 0.91
Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol Ther (2009) 0.91
Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood (2011) 0.90
Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. J Clin Invest (2015) 0.88
Structure-function analysis of the WIP role in T cell receptor-stimulated NFAT activation: evidence that WIP-WASP dissociation is not required and that the WIP NH2 terminus is inhibitory. J Biol Chem (2007) 0.88
Why newborn screening for severe combined immunodeficiency is essential: a case report. Pediatrics (2010) 0.88
Pain management within the palliative and end-of-life care experience in the ICU. Chest (2009) 0.88
Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. Blood (2003) 0.87
SLAM-associated protein deficiency causes imbalanced early signal transduction and blocks downstream activation in T cells from X-linked lymphoproliferative disease patients. J Biol Chem (2003) 0.87
In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals. Blood (2003) 0.87
Measurement of proliferative responses of cultured lymphocytes. Curr Protoc Immunol (2008) 0.87
A peek at PIAS. Nat Immunol (2004) 0.85
Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome. Blood (2008) 0.85
Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. Hum Gene Ther (2002) 0.85
Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. J Exp Med (2012) 0.85
Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells. Blood (2002) 0.85
Cytohesin binder and regulator (cybr) is not essential for T- and dendritic-cell activation and differentiation. Mol Cell Biol (2006) 0.85
Defective inhibition of B-cell proliferation by Wiskott-Aldrich syndrome protein-deficient regulatory T cells. Blood (2011) 0.85
Measurement of proliferative responses of cultured lymphocytes. Curr Protoc Immunol (2011) 0.84
FOXP3+ Tregs require WASP to restrain Th2-mediated food allergy. J Clin Invest (2016) 0.84
Pharmacokinetics and organ distribution of N-methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene. Cancer Chemother Pharmacol (2002) 0.83
Diagnosis of 22q11.2 deletion syndrome and artemis deficiency in two children with T-B-NK+ immunodeficiency. J Clin Immunol (2012) 0.83